BidaskClub downgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a sell rating in a research report released on Friday, January 24th, BidAskClub reports.
ICPT has been the topic of a number of other research reports. B. Riley increased their price target on Intercept Pharmaceuticals from $133.00 to $158.00 and gave the stock a buy rating in a research report on Thursday, January 9th. Stifel Nicolaus increased their price target on Intercept Pharmaceuticals from $86.00 to $102.00 in a research report on Monday, November 25th. Jefferies Financial Group set a $125.00 target price on Intercept Pharmaceuticals and gave the company a buy rating in a research report on Friday, October 18th. Raymond James decreased their target price on Intercept Pharmaceuticals from $148.00 to $147.00 and set a strong-buy rating on the stock in a research report on Monday, October 21st. Finally, Canaccord Genuity began coverage on Intercept Pharmaceuticals in a research report on Monday, December 2nd. They issued a buy rating on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of Buy and a consensus price target of $141.65.
Intercept Pharmaceuticals stock opened at $95.17 on Friday. The business’s 50-day moving average price is $109.19 and its 200 day moving average price is $84.06. The company has a quick ratio of 5.49, a current ratio of 5.49 and a debt-to-equity ratio of 4.02. Intercept Pharmaceuticals has a 52 week low of $56.76 and a 52 week high of $131.87.
In other news, General Counsel Ryan T. Sullivan sold 500 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $85.00, for a total value of $42,500.00. Following the completion of the sale, the general counsel now directly owns 26,929 shares of the company’s stock, valued at $2,288,965. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christian Weyer sold 723 shares of Intercept Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $94.04, for a total value of $67,990.92. Following the completion of the sale, the executive vice president now directly owns 18,560 shares of the company’s stock, valued at $1,745,382.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,880 shares of company stock valued at $5,721,929. 5.00% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICPT. Jennison Associates LLC grew its stake in Intercept Pharmaceuticals by 0.6% in the fourth quarter. Jennison Associates LLC now owns 168,706 shares of the biopharmaceutical company’s stock worth $20,906,000 after purchasing an additional 1,039 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in Intercept Pharmaceuticals by 102.4% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 14,980 shares of the biopharmaceutical company’s stock worth $1,856,000 after acquiring an additional 7,580 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Intercept Pharmaceuticals by 1.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 163,811 shares of the biopharmaceutical company’s stock worth $20,300,000 after acquiring an additional 3,125 shares during the last quarter. Sowell Financial Services LLC lifted its holdings in Intercept Pharmaceuticals by 469.6% in the fourth quarter. Sowell Financial Services LLC now owns 655 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 540 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Intercept Pharmaceuticals by 6.7% in the fourth quarter. Victory Capital Management Inc. now owns 3,895 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 244 shares during the last quarter. 79.14% of the stock is owned by hedge funds and other institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Intercept Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
